Sunshine Biopharma Expands Anti-Coronavirus Drug Development Program By Signing A Collaboration Agreement With The University Of Arizona
February 25 2022 - 8:00AM
Sunshine Biopharma Inc. (NASDAQ: “SBFM” and SBFMW) (the “Company”
or “Sunshine Biopharma”), a pharmaceutical company focused on the
research, development and commercialization of oncology and
antiviral drugs today announced that it has entered into an
agreement with the University of Arizona for the purposes of
advancing the development of novel PLpro inhibitors discovered by
University of Arizona and University of Illinois Chicago
researchers. The development of the Company’s lead PLpro inhibitor,
SBFM-PL4, is currently continuing at the University of Georgia. At
the University of Arizona, the research effort will focus on
determining the in vivo safety, pharmacokinetics, and dose
selection properties of 3 university owned PLpro inhibitors
followed by efficacy testing in MA10 mice infected with SARS-CoV-2.
Molecules showing efficacy in infected mice will be advanced to
human trials.
“We are delighted to be working with the
University of Arizona Coronavirus research team led by Dr. Gregory
Thatcher as well as the commercialization team at Tech Launch
Arizona,” said Dr. Steve Slilaty, CEO of Sunshine Biopharma. “It is
of paramount importance to find a wide array of inhibitors for
PLpro, as this virus encoded protease is responsible for
suppression of the human immune system thereby enabling the virus
to cause severe illness,” he added.
About the University of
Arizona
The University of Arizona, a land-grant
university with two independently accredited medical schools, is
one of the nation's top 50 public universities, according to U.S.
News & World Report. Established in 1885, the university is
widely recognized as a student-centric university and has been
designated as a Hispanic Serving Institution by the U.S. Department
of Education. The university ranked in the top 20 in 2019 in
research expenditures among all public universities, according to
the National Science Foundation, and is a leading Research 1
institution with $734 million in annual research expenditures. The
university advances the frontiers of interdisciplinary scholarship
and entrepreneurial partnerships as a member of the Association of
American Universities, the 66 leading public and private research
universities in the U.S. It benefits the state with an estimated
economic impact of $4.1 billion annually.
About Tech Launch Arizona
Tech Launch Arizona is the office of the
University of Arizona that creates social and economic impact
through commercializing inventions stemming from university
research. The office builds connections between talented UA
faculty, researchers and staff and experienced entrepreneurs and
investors, to create an ecosystem that refines ideas that
start in research and innovation and grows them into
products and businesses that benefit society. TLA supports
entrepreneurship through a variety of initiatives, including
training startup teams in customer discovery, providing funding to
advance early-stage inventions toward market readiness, and hosting
challenges to help students and faculty move innovative ideas from
concept to societal impact. In FY2021, TLA took in 274 invention
disclosures, had 100 U.S. patents issued, and executed 124 licenses
and options for UArizona technologies. The university has launched
more than 100 startups since the office was founded in 2012.
About Sunshine Biopharma
In addition, to working on the development of a
treatment for COVID-19, Sunshine Biopharma is engaged in the
development Adva-27a, a unique anticancer compound. Tests conducted
to date have demonstrated the effectiveness of Adva-27a at
destroying Multidrug Resistant Cancer Cells, including Pancreatic
Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells,
and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer
indication are planned to be conducted at McGill University’s
Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is
owner of all patents and intellectual property pertaining to
Adva-27a.
Safe Harbor Forward-Looking
Statements
This press release may contain forward looking
statements which are based on current expectations, forecasts, and
assumptions of Sunshine Biopharma, Inc. (the “Company”) that
involve risks as well as uncertainties that could cause actual
outcomes and results to differ materially from those anticipated or
expected. These statements appear in a number of places in this
release and include all statements that are not statements of
historical fact regarding the intent, belief or current
expectations of the Company, including statements related to the
Company’s drug development activities, financial performance, and
future growth. These risks and uncertainties are
further described in filings and reports by the Company with the
U.S. Securities and Exchange Commission (SEC). Actual results and
the timing of certain events could differ materially from those
projected in or contemplated by the forward-looking statements due
to a number of factors detailed from time to time in the Company’s
filings with the SEC. Reference is hereby made to cautionary
statements and risk factors set forth in the Company's most recent
SEC filings.
For Additional Information:
Camille Sebaaly, CFODirect Line:
514-814-0464camille.sebaaly@sunshinebiopharma.comwww.sunshinebiopharma.com
Sunshine Biopharma (NASDAQ:SBFMW)
Historical Stock Chart
From Sep 2024 to Oct 2024
Sunshine Biopharma (NASDAQ:SBFMW)
Historical Stock Chart
From Oct 2023 to Oct 2024